MXPA03009411A - COMPOSICIoN FARMACeUTICA SUMINISTRABLE ORALMENTE QUE COMPRENDE UN MEDICAMENTO DE POCA HIDROSUBILIDAD (INHIBIDOR DE COX-2), UN SOLVENTE, UN ACIDO GRASO Y UNA AMINA ORGANICA. - Google Patents

COMPOSICIoN FARMACeUTICA SUMINISTRABLE ORALMENTE QUE COMPRENDE UN MEDICAMENTO DE POCA HIDROSUBILIDAD (INHIBIDOR DE COX-2), UN SOLVENTE, UN ACIDO GRASO Y UNA AMINA ORGANICA.

Info

Publication number
MXPA03009411A
MXPA03009411A MXPA03009411A MXPA03009411A MXPA03009411A MX PA03009411 A MXPA03009411 A MX PA03009411A MX PA03009411 A MXPA03009411 A MX PA03009411A MX PA03009411 A MXPA03009411 A MX PA03009411A MX PA03009411 A MXPA03009411 A MX PA03009411A
Authority
MX
Mexico
Prior art keywords
cox
inhibitor
drug
solvent
pharmaceutical composition
Prior art date
Application number
MXPA03009411A
Other languages
English (en)
Spanish (es)
Inventor
Karim Aziz
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA03009411A publication Critical patent/MXPA03009411A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MXPA03009411A 2001-04-17 2002-04-12 COMPOSICIoN FARMACeUTICA SUMINISTRABLE ORALMENTE QUE COMPRENDE UN MEDICAMENTO DE POCA HIDROSUBILIDAD (INHIBIDOR DE COX-2), UN SOLVENTE, UN ACIDO GRASO Y UNA AMINA ORGANICA. MXPA03009411A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28438101P 2001-04-17 2001-04-17
US32695201P 2001-10-04 2001-10-04
PCT/US2002/011689 WO2002083177A1 (en) 2001-04-17 2002-04-12 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine

Publications (1)

Publication Number Publication Date
MXPA03009411A true MXPA03009411A (es) 2004-01-29

Family

ID=26962574

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009411A MXPA03009411A (es) 2001-04-17 2002-04-12 COMPOSICIoN FARMACeUTICA SUMINISTRABLE ORALMENTE QUE COMPRENDE UN MEDICAMENTO DE POCA HIDROSUBILIDAD (INHIBIDOR DE COX-2), UN SOLVENTE, UN ACIDO GRASO Y UNA AMINA ORGANICA.

Country Status (18)

Country Link
US (1) US20030105141A1 (https=)
EP (1) EP1379279A1 (https=)
JP (1) JP2004530669A (https=)
KR (1) KR20040018355A (https=)
CN (1) CN1516601A (https=)
AR (1) AR033221A1 (https=)
AU (1) AU2002305175B2 (https=)
BR (1) BR0208994A (https=)
CA (1) CA2444220A1 (https=)
CZ (1) CZ20032792A3 (https=)
EA (1) EA008103B1 (https=)
IL (1) IL158201A0 (https=)
MX (1) MXPA03009411A (https=)
NO (1) NO20034629L (https=)
NZ (1) NZ528741A (https=)
PE (1) PE20021145A1 (https=)
PL (1) PL364524A1 (https=)
WO (1) WO2002083177A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1344523A1 (en) * 2002-03-11 2003-09-17 Warner-Lambert Company Ibuprofen solution for hard gelatin capsules
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US20060141470A1 (en) * 2003-02-14 2006-06-29 Kalayoglu Murat V Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
SI2279729T1 (sl) * 2003-07-17 2016-10-28 Banner Life Sciences, LLC Pripravki z nadziranim sproščanjem
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MX2007009888A (es) * 2005-02-17 2007-10-16 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
CN101351196B (zh) 2005-10-26 2013-07-03 班纳制药公司 作为胶囊填充物的基于亲脂性载体的双重控释基质系统
CA2627292C (en) * 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
US8999381B2 (en) * 2007-09-27 2015-04-07 Wockhardt Ltd. Self-emulsifying pharmaceutical compositions of rhein or diacerein
MX2011005643A (es) * 2008-12-03 2011-09-27 Astellas Deutschland Gmbh Formas de dosificacion oral de bendamustina.
US9717703B2 (en) 2009-10-16 2017-08-01 Glaxosmithkline Llc Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
JO3587B1 (ar) * 2010-06-02 2020-07-05 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
WO2013058303A1 (ja) * 2011-10-18 2013-04-25 ラクオリア創薬株式会社 医薬組成物
KR102235264B1 (ko) * 2013-01-14 2021-04-02 인퍼스트 헬스케어 리미티드 고용체 조성물들 및 심각한 통증에서의 이들의 용도
CA2898017A1 (en) * 2013-02-04 2014-08-07 Infirst Healthcare Limited Compositions and methods for treating chronic inflammation and inflammatory diseases
EP3043648B1 (en) 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
CN109477010B (zh) 2016-07-05 2021-07-23 戈登可再生能源有限公司 用于将废弃塑料转化成燃料的系统和工艺
US12213510B2 (en) 2019-09-11 2025-02-04 Nicoventures Trading Limited Pouched products with enhanced flavor stability
CN113750043A (zh) * 2021-09-18 2021-12-07 山东省药学科学院 一种塞来昔布自乳化口服液及其制备方法
WO2024142089A1 (en) * 2022-12-27 2024-07-04 Cipla Limited Injectable compositions of celecoxib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69422306T4 (de) * 1993-11-30 2000-09-07 G.D. Searle & Co., Chicago Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
CA2301304A1 (en) * 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
AU2001282886A1 (en) * 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain

Also Published As

Publication number Publication date
CA2444220A1 (en) 2002-10-24
NO20034629D0 (no) 2003-10-16
EP1379279A1 (en) 2004-01-14
PL364524A1 (en) 2004-12-13
CN1516601A (zh) 2004-07-28
AR033221A1 (es) 2003-12-10
KR20040018355A (ko) 2004-03-03
WO2002083177A1 (en) 2002-10-24
JP2004530669A (ja) 2004-10-07
EA008103B1 (ru) 2007-04-27
CZ20032792A3 (cs) 2004-04-14
AU2002305175B2 (en) 2007-07-12
PE20021145A1 (es) 2003-01-16
IL158201A0 (en) 2004-05-12
BR0208994A (pt) 2004-04-27
NZ528741A (en) 2005-09-30
US20030105141A1 (en) 2003-06-05
NO20034629L (no) 2003-12-10
EA200301019A1 (ru) 2004-06-24

Similar Documents

Publication Publication Date Title
MXPA03009411A (es) COMPOSICIoN FARMACeUTICA SUMINISTRABLE ORALMENTE QUE COMPRENDE UN MEDICAMENTO DE POCA HIDROSUBILIDAD (INHIBIDOR DE COX-2), UN SOLVENTE, UN ACIDO GRASO Y UNA AMINA ORGANICA.
ITMI20021660A1 (it) Sistema di somministrazione di farmaco bioadesivo
IL216686A (en) Ritonavir-containing drug solution and organic solvent containing a mixture of long fatty acids and water
CY2013023I1 (el) Φαρμακο για την υπερδραστηρια ουροδοχο κυστη περιλαμβανον παραγωγο ανιλιδιου οξικου οξεος ως το ενεργο συστατικο
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
MXPA03009410A (es) COMPOSICIoN FARMACEUTICA QUE SE ADMINISTRA ORALMENTE QUE COMPRENDE UN COMPUESTO ACTIVO QUE TIENE UN GRUPO AMINOSULFONILO (INHIBIDOR COX-2) UN POLIETILEN GLICOL Y UN ANTIOXIDANTE DEPURADOR DE RADICALES LIBRES.
AU2002350719A1 (en) Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
NO20031784D0 (no) Heteroarylalkylpiperazinderivater som fettsyre- oksydasjonsinhibitorer
NO2014005I1 (no) olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav
IL163642A0 (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
HUP0401963A3 (en) Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
SI1258476T1 (sl) Derivati alfa-aminokislin, postopek za njihovo pripravo in njihova uporaba kot inhibitorji dopeptidil-peptidaze iv (dpp iv)
AU2001298061A1 (en) Microencapsulation of drugs by solvent exchange
WO2003086392A3 (en) Process for preparing a finely self-emulsifiable pharmaceutical composition
WO2002008217A3 (en) COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
CA2515293A1 (en) Eicosapentaenoic acid for use in improving prognosis in the treatment of subarachnoid hemorrhage
ITMI20011401A0 (it) Formulazioni farmaceutiche per ormoni tiroidei
AR079399A2 (es) Procedimientos para preparar bifenazato
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU3408901A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
IL170316A (en) Cycloalkyl-methoxy substituted acetic acid derivatives and pharmaceutical compositions comprising them
HUP0303694A3 (en) Aza-amino acid derivatives and pharmaceutical
AU2003260239A1 (en) Solid dosage forms for rapid dissolution of poorly soluble drugs
GB2398005B (en) Orally administrable pharmaceutical formulation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal